Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle Through Phosphoinositide 3-Kinase Signaling and Ikaros Expression Richard J

Total Page:16

File Type:pdf, Size:1020Kb

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle Through Phosphoinositide 3-Kinase Signaling and Ikaros Expression Richard J Cancer Therapy: Preclinical Clinical Cancer Research Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression Richard J. Jones1, Tawin Iempridee2, Xiaobin Wang3, Hans C. Lee1, Janet E. Mertz4, Shannon C. Kenney4, Heather C. Lin5, Veerabhadran Baladandayuthapani5, Christopher W. Dawson6, Jatin J. Shah1, Donna M. Weber1, and Robert Z. Orlowski1,7 Abstract Purpose: Lenalidomide, thalidomide, and pomalidomide early gene BZLF1, the early gene BMRF1, and the late proteins VCA (LTP) are immunomodulatory agents approved for use in mul- and BCFR1. This occurred in the potency order pomalidomide > tiple myeloma, but in some settings, especially with alkylating lenalidomide > thalidomide, and the nucleoside analogue gan- agents, an increase in Hodgkin lymphoma and other secondary ciclovir enhanced the cytotoxic effects of lenalidomide and poma- primary malignancies (SPM) has been noted. Some of these lidomide in Burkitt lymphoma cells in vitro and in vivo. EBV malignancies have been linked to Epstein–Barr virus (EBV), reactivation was related to PI3K stimulation and Ikaros suppres- raising the possibility that immunomodulatory drugs disrupt sion, and blocked by the PI3Kd inhibitor idelalisib. Combina- latent EBV infection. tions of lenalidomide with dexamethasone or rituximab Experimental Design: We studied the ability of LTP to reacti- increased EBV reactivation compared with lenalidomide alone vate latently infected EBV-positive cell lines in vitro and in vivo, and and, importantly, lenalidomide with melphalan produced even evaluated the EBV viral load in archived serum samples from greater reactivation. patients who received a lenalidomide, thalidomide, and dexa- Conclusions: We conclude LTP may reactivate EBV-positive methasone (LTD) combination. resting memory B cells thereby enhancing EBV lytic cycle and Results: Treatment of EBV-infected B-cell lines with LTP at host immune suppression. Clin Cancer Res; 22(19); 4901–12. Ó2016 physiologically relevant concentrations induced the immediate AACR. Introduction tings. Moreover, lenalidomide is now included in maintenance therapy (MT) in both transplant-eligible and transplant-ineligible The immunomodulatory drugs lenalidomide, thalidomide, populations (2–4). and pomalidomide (LTP) have contributed to an improvement Although the efficacy of LTP is without question, concern has in survival in patients with multiple myeloma (1). Consequently, arisen about a possible increase in secondary primary malignan- they have become part of the backbone of many therapeutic cies (SPM). This has been seen with maintenance after melphalan- regimens in the upfront, relapsed, and relapsed/refractory set- based high-dose chemotherapy and autologous stem cell trans- plant (SCT; refs. 2, 3), or following melphalan-based induction 1Department of Lymphoma and Myeloma, The University of Texas MD therapy (4). Interestingly, lenalidomide maintenance increased Anderson Cancer Center, Houston, Texas. 2National Nanotechnology the incidence of Hodgkin lymphoma in two studies, an uncom- Center (NANOTEC), National Science and Technology Development mon SPM seen in patients with multiple myeloma. Indeed, Attal Agency (NSTDA), Pathum Thani, Thailand. 3Urology Department, ShengJing Hospital, China Medical University, ShenYang, China. and colleagues reported four Hodgkin lymphoma cases in 4McArdle Laboratory for Cancer Research, University of Wisconsin patients with multiple myeloma who had undergone SCT and School of Medicine and Public Health, Madison, Wisconsin. 5Depart- none in the placebo group (2), whereas McCarthy reported one ment of Biostatistics, The University of Texas MD Anderson Cancer case (3). Moreover, a retrospective analysis of three phase III trials Center, Houston, Texas. 6Birmingham Cancer Research UK Cancer Centre, School of Cancer Sciences, University of Birmingham, Bir- in relapsed patients with multiple myeloma demonstrated an mingham, United Kingdom. 7Department of Experimental Therapeu- SPM incidence of 4% in patients who received lenalidomide tics, The University of Texas MD Anderson Cancer Center, Houston, versus 1.4% in those who received placebo (5). Texas. One possible reason for the development of Hodgkin lympho- Note: Supplementary data for this article are available at Clinical Cancer ma as an SPM is reactivation of Epstein–Barr virus (EBV). This Research Online (http://clincancerres.aacrjournals.org/). oncogenic gamma herpes virus is associated with, and contributes Corresponding Author: Richard J. Jones, University of Texas MD Anderson to the development and maintenance of a variety of human Cancer Center, 7455 Fannin ST, Unit 403, SCR2.3206, Houston, TX 77054. malignancies, including Hodgkin lymphoma, Burkitt lymphoma, Phone: 713-745-5654; Fax: 713-792-6887; E-mail: [email protected] and posttransplant lymphoproliferative disease (PTLD; ref. 6). doi: 10.1158/1078-0432.CCR-15-2242 Primary infection occurs during childhood, and lifelong infection Ó2016 American Association for Cancer Research. is maintained latently in resting memory B cells, with occasional www.aacrjournals.org 4901 Jones et al. in DMSO, except for melphalan, which was dissolved in ethanol, Translational Relevance and rituximab, which was in 0.9% sodium chloride. The expanding use of immunomodulatory drugs in multi- ple myeloma, other hematologic malignancies, and diseases Cell culture and patient samples other than cancer demonstrates the potential effectiveness of MUTU-I and KEM-I (gifts from Alan Rickinson [Birmingham this class of agents. Their long-term use, such as in the main- Cancer Research UK Cancer Centre, School of Cancer Sciences, tenance therapy setting, however, may reveal previously University of Birmingham, Birmingham, United Kingdom] and Jeff unidentified downstream effects and toxicities. Our findings Sample [Department of Microbiology and Immunology, The Penn- sylvania State University College of Medicine, Pennsylvania]), are show the reactivation of the Epstein–Barr virus (EBV) into its þ þ lytic life cycle from a previously latent state occurs primarily EBV Burkitt lymphoma cell lines. The EBV Burkitt lymphoma cell through the stimulation of PI3K signaling. This phenomenon line DAUDI and the lymphoblastoid cell line (LCL) B95.8 were has the potential to be a novel therapeutic strategy against EBV- from the ATCC, whereas the donor 4 (D4-WT) LCL and BZLF-1 positive malignancies in combination with ganciclovir. How- deleted LCL (D4-ZKO) were described previously (12). All lines ever, these findings also raise concern about the immunosup- were validated through The MD Anderson Cancer Center Charac- pressive effects of these drugs, and provides a possible link to terized Cell Line Core Facility. Cells were grown in RPMI1640 (Life m EBV-related second primary malignancies. Technologies) with 10% FBS, 100 U/mL penicillin, and 100 g/mL streptomycin (Sigma-Aldrich). Archived serum samples were sourced from patients with myeloma enrolled in a phase I/II clinical trial (13), which was in compliance with the Declaration of Helsinki viral reactivation. In the absence of immune control, such as in according to an Institutional Review Board–approved protocol. patients who undergo SCT, loss of EBV control can give rise to PTLD (7). The use of HYPER-CVAD regimens in leukemia and Immunoblotting lymphoma patients, and methotrexate use in patients with auto- Protein expression was measured by immunoblot analysis as immune disease, increases the incidence of EBV-positive lympho- described previously (14). The antibody to BZLF-1 was from Santa a mas (8, 9). It is also interesting to note that lenalidomide-MT in Cruz Biotechnology, whereas the anti-AKT, phospho (p)-GSK3 / bSer21/9 473 relapsed/refractory multiple myeloma patients following allo- , p-AKTSer , FoxO1, and Ikaros antibodies were from graft SCT induced herpes virus reactivation (EBV and herpes Cell Signaling Technology. Antibody to BMRF1 was obtained b simplex virus) requiring acyclovir prophylaxis (10). In contrast, from Millipore, anti- -actin from Sigma-Aldrich, and anti-VCA fi chemotherapeutics such as doxorubicin or gemcitabine have been p18 antibodies were from Thermo Scienti c. Total AKT and SER473 shown to reactivate EBV from a latent infection in EBV-positive pAKT levels were also measured using sandwich ELISA Kit malignancies to a lytic infection, which has led to clinically as recommended by the manufacturer Cell Signaling Technology. significant regression of EBV-positive tumors (11). Hence, the ability of chemotherapy agents to induce lytic EBV infection can Cell proliferation assay be a therapeutic modality for EBV-positive malignancies in com- The WST-1 tetrazolium reagent from Roche was used to deter- bination with the nucleoside analogue ganciclovir, or it could give mine the effects on cell proliferation. Viable cell numbers rise to secondary EBV-positive malignancies in immunocompro- (Annexin-V- and TO-PRO-3-negative) were measured using fi mised hosts. These possibilities drove us to determine whether Annexin-V-Paci c Blue and TO-PRO-3 (Life Technologies) in fl lenalidomide reactivates the EBV lytic cycle, which could sensitize combination with Count Bright Beads on a Fortessa ow cytometer tumor cells to the effects of ganciclovir and/or contribute to the (Becton Dickson) using FlowJo, version 10 (Tree Star, Inc.). development of Hodgkin lymphoma as an SPM. Blockade of PI3K signaling Here we show that LTP reactivated lytic EBV infection
Recommended publications
  • Revlimid U.S. Full Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION • FL or MZL: 20 mg once daily orally on Days 1-21 of repeated 28-day cycles for up to These highlights do not include all the information needed to use REVLIMID® safely 12 cycles (2.4). and effectively. See full prescribing information for REVLIMID. • Renal impairment: Adjust starting dose based on the creatinine clearance value (2.6). • For concomitant therapy doses, see Full Prescribing Information (2.1, 2.4, 14.1, 14.4). REVLIMID (lenalidomide) capsules, for oral use Initial U.S. Approval: 2005 ------------------------- DOSAGE FORMS AND STRENGTHS ------------------------- Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg (3). WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, -------------------------------- CONTRAINDICATIONS -------------------------------- and VENOUS and ARTERIAL THROMBOEMBOLISM • Pregnancy (Boxed Warning, 4.1, 5.1, 8.1). See full prescribing information for complete boxed warning. • Demonstrated severe hypersensitivity to lenalidomide (4.2, 5.9, 5.15). EMBRYO-FETAL TOXICITY --------------------------- WARNINGS AND PRECAUTIONS --------------------------- • Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study similar to birth defects caused by thalidomide • Increased Mortality: serious and fatal cardiac adverse reactions occurred in patients in humans. If lenalidomide is used during pregnancy, it may cause birth with CLL treated with REVLIMID (lenalidomide) (5.5). defects or embryo-fetal death. • Second Primary Malignancies (SPM): Higher incidences of SPM were observed in • Pregnancy must be excluded before start of treatment. Prevent pregnancy controlled trials of patients with MM receiving REVLIMID (5.6). during treatment by the use of two reliable methods of contraception (5.1). • Increased Mortality: Observed in patients with MM when pembrolizumab was added REVLIMID is available only through a restricted distribution program, called the to dexamethasone and a thalidomide analogue (5.7).
    [Show full text]
  • Revlimid-INN Lenalidomide
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Revlimid 2.5 mg hard capsules Revlimid 5 mg hard capsules Revlimid 7.5 mg hard capsules Revlimid 10 mg hard capsules Revlimid 15 mg hard capsules Revlimid 20 mg hard capsules Revlimid 25 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Revlimid 2.5 mg hard capsules Each capsule contains 2.5 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 73.5 mg of lactose (as anhydrous lactose). Revlimid 5 mg hard capsules Each capsule contains 5 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 147 mg of lactose (as anhydrous lactose). Revlimid 7.5 mg hard capsules Each capsule contains 7.5 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 144.5 mg of lactose (as anhydrous lactose). Revlimid 10 mg hard capsules Each capsule contains 10 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 294 mg of lactose (as anhydrous lactose). Revlimid 15 mg hard capsules Each capsule contains 15 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 289 mg of lactose (as anhydrous lactose). Revlimid 20 mg hard capsules Each capsule contains 20 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 244.5 mg of lactose (as anhydrous lactose).
    [Show full text]
  • Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
    cancers Review Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma Fatih M. Uckun 1,2,3 1 Norris Comprehensive Cancer Center and Childrens Center for Cancer and Blood Diseases, University of Southern California Keck School of Medicine (USC KSOM), Los Angeles, CA 90027, USA; [email protected] 2 Department of Developmental Therapeutics, Immunology, and Integrative Medicine, Drug Discovery Institute, Ares Pharmaceuticals, St. Paul, MN 55110, USA 3 Reven Pharmaceuticals, Translational Oncology Program, Golden, CO 80401, USA Simple Summary: This article provides a comprehensive review of new and emerging treatment strategies against multiple myeloma that employ precision medicines and/or drugs capable of improving the ability of the immune system to prevent or slow down the progression of multiple myeloma. These rationally designed new treatment methods have the potential to change the therapeutic landscape in multiple myeloma and improve the long-term survival outcome. Abstract: SeverFigurel cellular elements of the bone marrow (BM) microenvironment in multiple myeloma (MM) patients contribute to the immune evasion, proliferation, and drug resistance of MM cells, including myeloid-derived suppressor cells (MDSCs), tumor-associated M2-like, “alter- natively activated” macrophages, CD38+ regulatory B-cells (Bregs), and regulatory T-cells (Tregs). These immunosuppressive elements in bidirectional and multi-directional crosstalk with each other inhibit both memory and cytotoxic effector T-cell populations as well as natural killer (NK) cells. Immunomodulatory imide drugs (IMiDs), protease inhibitors (PI), monoclonal antibodies (MoAb), Citation: Uckun, F.M. Overcoming the Immunosuppressive Tumor adoptive T-cell/NK cell therapy, and inhibitors of anti-apoptotic signaling pathways have emerged as Microenvironment in Multiple promising therapeutic platforms that can be employed in various combinations as part of a rationally Myeloma.
    [Show full text]
  • In Relapsed Or Refractory Diffuse
    Dührsen et al. Blood Cancer Journal (2021) 11:95 https://doi.org/10.1038/s41408-021-00485-5 Blood Cancer Journal CORRESPONDENCE Open Access Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma Ulrich Dührsen 1, Mareike Tometten2,FrankKroschinsky3, Arnold Ganser4,StefanIbach5, Stefanie Bertram6 and Andreas Hüttmann 1 Dear Editor, ≥2.5 mg/dl, serum aspartate [AST] or alanin amino- Lenalidomide has moderate activity in relapsed or transferase [ALT] >4× upper limit of normal [ULN]), refractory diffuse large B cell lymphoma (r/rDLBCL)1. active hepatitis B or C, human immunodeficiency virus Based on the COMLA regimen used in the 1970s and infection, any other uncontrolled infection, as well as 1980s2, we combined lenalidomide with methotrexate pregnancy and nursing period. All patients gave written (plus leucovorin), cytarabine, and rituximab (LeMLAR) in informed consent. The LeMLAR regimen (Fig. 1) com- a phase I/II trial. Lenalidomide induces apoptosis and cell prised up to six 28-day cycles consisting of lenalidomide cycle arrest in the G0/G1 phase3. After discontinuation, (day 1–21), methotrexate (5–10 min i.v. bolus; day 1, 8, surviving cells start to proliferate and become susceptible 15), leucovorin (four oral 45 mg doses six hours apart, to the S-phase-specific agents methotrexate and cytar- starting 24 h after methotrexate), cytarabine (5-10 min i.v. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; abine administered in the subsequent cycle. Because of bolus; day 1, 8, 15), and rituximab (375 mg/m², day 1). All – low toxicity for immune effector cells4 6, these drugs are patients received prophylactic enoxaparin (40 mg s.c.).
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Australian Pi – Pomalyst (Pomalidomide) Capsules
    AUSTRALIAN PI – POMALYST (POMALIDOMIDE) CAPSULES Teratogenic effects: Pomalyst (pomalidomide) is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If pomalidomide is taken during pregnancy, it may cause birth defects or death to an unborn baby. Women should be advised to avoid pregnancy whilst taking Pomalyst (pomalidomide), during dose interruptions, and for 4 weeks after stopping the medicine. 1 NAME OF THE MEDICINE Australian Approved Name: pomalidomide 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 mg capsule contains 1 mg pomalidomide. Each 2 mg capsule contains 2 mg pomalidomide. Each 3 mg capsule contains 3 mg pomalidomide. Each 4 mg capsule contains 4 mg pomalidomide. For the full list of excipients, see Section 6.1. Description Pomalidomide is a yellow solid powder. It is practically insoluble in water over the pH range 1.2-6.8 and is slightly soluble (eg. acetone, methylene chloride) to practically insoluble (eg. heptanes, ethanol) in organic solvents. Pomalidomide has a chiral carbon atom and exists as a racemic mixture of the R(+) and S(-) enantiomers. 3 PHARMACEUTICAL FORM Pomalyst (pomalidomide) 1 mg capsules: dark blue/yellow size 4 gelatin capsules marked “POML” in white ink and “1 mg” in black ink. Each 1 mg capsule contains 1 mg of pomalidomide. Pomalyst (pomalidomide) 2 mg capsules: dark blue/orange size 2 gelatin capsules marked “POML 2 mg” in white ink. Each 2 mg capsule contains 2 mg of pomalidomide. Pomalyst (pomalidomide) 3 mg capsules: dark blue/green size 2 gelatin capsules marked “POML 3 mg” in white ink.
    [Show full text]
  • Pomalidomide the POMALYST® Program
    Pomalidomide The POMALYST® Program Overview Multiple myeloma is a type of cancer that begins in plasma cells in bone marrow. Plasma cells are white blood cells that make antibodies. The abnormal plasma cells build up in the bone marrow and sometimes in the solid part of the bone. Pomalidomide (brand name Pomalyst®) is approved to treat certain patients with multiple myeloma, but only under a restricted distribution program. Before you start taking this drug, you and your loved ones should read the important information in this brochure about the medication, side effects, and the rules you must follow if you choose pomalidomide, including the requirement to use birth control. Safety Pomalidomide is similar to the drug thalidomide and can cause the same life threatening birth defects. Both medications are approved by the Food and Drug Administration (FDA) to treat multiple myeloma within restricted distribution programs. For pomalidomide, the program is called Pomalyst REMS™ (Risk Evaluation and Mitigation Strategy). The program is in place to make sure that everyone is following the established safety guidelines. Only providers (doctors, nurse practitioners, etc.) and pharmacies certified by this program can write prescriptions for this medication or dispense it. To be considered for pomalidomide: • you must have already tried at least 2 other therapies, including lenalidomide and bortezomib • your disease must have progressed within 60 days of completing your last therapy • you must enroll in the Pomalyst REMS program and agree to comply with the program’s requirements (detailed in this brochure) Your healthcare provider will counsel you about the risks and benefits of this therapy.
    [Show full text]
  • Safety and Tolerability of Lenalidomide Maintenance in Post-Transplant
    www.nature.com/bmt ARTICLE OPEN Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome ✉ Brian Pham 1 , Rasmus Hoeg1, Rajeev Krishnan2, Carol Richman1, Joseph Tuscano1 and Mehrdad Abedi 1 © The Author(s) 2021 Relapse after allogeneic stem cell transplant in unfavorable-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) portends a poor prognosis. We conducted a single-center phase I dose-escalation study with lenalidomide maintenance in high-risk MDS and AML patients after allogeneic transplantation. Sixteen patients enrolled in a “3 + 3” study design starting at lenalidomide 5 mg daily, increasing in increments of 5 mg up to 15 mg. Lenalidomide was given for 21 days of a 28-day cycle for a total of six cycles. Most common dose-limiting toxicities were lymphopenia, diarrhea, nausea, and neutropenia. Two patients had acute graft-versus-host disease (GVHD), and five patients developed chronic GVHD. The maximum tolerated dose was 10 mg, after dose-limiting toxicities were seen in the 15 mg group. Two dose-limiting toxicities were seen from development of acute GVHD and grade III diarrhea. Limitations of the study include time to initiation at 6 months post transplant, as many high-risk patients will have relapsed within this time frame before starting maintenance lenalidomide. Overall, lenalidomide was well tolerated with minimal GVHD and low rates of relapse rates, warranting further study. Bone Marrow Transplantation; https://doi.org/10.1038/s41409-021-01444-1 INTRODUCTION mutations, the role for post-transplant maintenance is less clear. Allogeneic stem cell transplantation (allo-SCT) remains the best Hypomethylating agents have been studied for post allo-SCT option for cure in most patients with unfavorable-risk acute maintenance therapy.
    [Show full text]
  • REVLIMID (Lenalidomide) 5 Mg, 10 Mg, 15 Mg and 25 Mg Capsules
    ® 1 REVLIMID (lenalidomide) 2 5 mg, 10 mg, 15 mg and 25 mg capsules 3 WARNINGS: 4 1. POTENTIAL FOR HUMAN BIRTH DEFECTS 5 2. HEMATOLOGIC TOXICITY (NEUTROPENIA AND 6 THROMBOCYTOPENIA) 7 3. DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM 8 9 POTENTIAL FOR HUMAN BIRTH DEFECTS 10 WARNING: POTENTIAL FOR HUMAN BIRTH DEFECTS 11 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS 12 A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE­ 13 THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN 14 DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN 15 UNBORN BABY. FEMALES SHOULD BE ADVISED TO AVOID PREGNANCY 16 WHILE TAKING REVLIMID® (lenalidomide). 17 Special Prescribing Requirements 18 BECAUSE OF THIS POTENTIAL TOXICITY AND TO AVOID FETAL 19 EXPOSURE TO REVLIMID® (lenalidomide), REVLIMID® (lenalidomide) IS 20 ONLY AVAILABLE UNDER A SPECIAL RESTRICTED DISTRIBUTION 21 PROGRAM. THIS PROGRAM IS CALLED "RevAssist®." UNDER THIS 22 PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED WITH 23 THE PROGRAM CAN PRESCRIBE AND DISPENSE THE PRODUCT. IN 24 ADDITION, REVLIMID® (lenalidomide) MUST ONLY BE DISPENSED TO 25 PATIENTS WHO ARE REGISTERED AND MEET ALL THE CONDITIONS OF 26 THE RevAssist® PROGRAM. 27 PLEASE SEE THE FOLLOWING INFORMATION FOR PRESCRIBERS, 28 FEMALE PATIENTS, AND MALE PATIENTS ABOUT THIS RESTRICTED 29 DISTRIBUTION PROGRAM. 30 RevAssist® PROGRAM DESCRIPTION 31 Prescribers 32 REVLIMID® (lenalidomide) can be prescribed only by licensed prescribers who are 33 registered in the RevAssist® program and understand the potential risk of teratogenicity if 34 lenalidomide is used during pregnancy. 1 35 Effective contraception must be used by female patients of childbearing potential for at 36 least 4 weeks before beginning REVLIMID® (lenalidomide) therapy, during 37 REVLIMID® (lenalidomide) therapy, during dose interruptions and for 4 weeks 38 following discontinuation of REVLIMID® (lenalidomide) therapy.
    [Show full text]
  • Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas by Ajay Major, Justin Kline, Theodore G
    Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas by Ajay Major, Justin Kline, Theodore G. Karrison, Paul A.S. Fishkin, Amy S. Kimball, Adam M. Petrich, Sreenivasa Nattam, Krishna Rao, Bethany G. Sleckman, Kenneth Cohen, Koen van Besien, Aaron P. Rapoport, and Sonali M. Smith Received: April 18, 2021. Accepted: July 22, 2021. Citation: Ajay Major, Justin Kline, Theodore G. Karrison, Paul A.S. Fishkin, Amy S. Kimball, Adam M. Petrich, Sreenivasa Nattam, Krishna Rao, Bethany G. Sleckman, Kenneth Cohen, Koen van Besien, Aaron P. Rapoport and Sonali M. Smith. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2021 Jul 29. doi: 10.3324/haematol.2021.278853. [Epub ahead of print] Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process. Phase I/II TEM/LEN clinical trial Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas Ajay Major1; Justin Kline1; Theodore G.
    [Show full text]
  • Australian Public Assessment Report for Apremilast
    Australian Public Assessment Report for Apremilast Proprietary Product Name: Otezla Sponsor: Celgene Pty Ltd October 2015 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs · An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Unsupported Price Increase Report
    Unsupported Price Increase Report 2019 Assessment October 8, 2019 (Updated November 6, 2019) ©Institute for Clinical and Economic Review, 2019 Authors David M. Rind, MD, MSc Eric Borrelli, PharmD, MBA Chief Medical Officer Evidence Synthesis Intern Institute for Clinical and Economic Review Institute for Clinical and Economic Review Foluso Agboola, MBBS, MPH Steven D. Pearson, MD, MSc Director, Evidence Synthesis President Institute for Clinical and Economic Review Institute for Clinical and Economic Review Varun M. Kumar, MBBS, MPH, MSc (Former) Associate Director of Health Economics Institute for Clinical and Economic Review None of the above authors disclosed any conflicts of interest. DATE OF PUBLICATION: October 8, 2019 (Updated November 6, 2019) We would also like to thank Laura Cianciolo and Maria M. Lowe for their contributions to this report. ©Institute for Clinical and Economic Review, 2019 Page ii Unsupported Price Increase Report About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at http://www.icer-review.org. The funding for this report comes from the Laura and John Arnold Foundation. No funding for this work comes from health insurers, pharmacy benefit managers (PBMs), or life science companies. ICER receives approximately 21% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies.
    [Show full text]